Did he mention this other orphan drug co.?
CUBT?
ANVS on Seeking Alpha:
Annovis Bio shares rise on positive data from ANVS401 Alzheimer's disease trial
May 21, 2021
Annovis Bio, Inc. (ANVS)Annovis Bio, Inc. (ANVS)
By: Aakash Babu, SA News Editor
Annovis Bio (NYSE:ANVS) announces promising results from a double-blind, placebo-controlled study of ANVS401, its lead drug candidate for the treatment of Alzheimer's disease (AD) and Parkinson's disease (PD).
Shares up more than 13% premarket.
Patients treated with ANVS401 for 25 days showed statistically significant cognitive improvement as measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11).
From baseline to 25 days in the ANVS401-treated group, ADAS-Cog11 improved by 4.4 points, a statistically significant improvement of 30% (p=0.04).
Additionally, the ANVS401-treated group compared to placebo group at 25 days showed an improvement of 3.3 points, or 22% (p= 0.13).
This is the first double-blind, placebo-controlled study that shows cognitive improvements in AD patients as measured by ADAS-Cog and functional improvements in PD patients as measured by the Unified Parkinson's Disease Rating Scale (UPDRS), the company said.
The safety profile of ANVS401 in the interim analysis was consistent with prior safety data that shows it to be safe at 80 mg once a day in humans. There were no adverse events that could have been ascribed to the drug treatment.
Assuming successful completion of its ongoing Phase 2a study, the company anticipates to advance ANVS401 into late-stage studies by late 2021.
Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
